57+ min ago   (672+ words) Manufacturing hurdles are just one challenge the industry must overcome to commercialize personalized mRNA cancer vaccines. The personalized cancer vaccine field leaped forward last month when Merck and Moderna’s personalized melanoma vaccine scored big in a phase 3 clinical trial. Moderna’s…...

23+ hour, 47+ min ago   (466+ words) The drugmaker hopes to move the needle on challenging cancers and shore up its pipeline as it prepares for the Keytruda patent cliff. Success in women’s oncology isn’t just about buying patients more time but making those added months or…...

2+ day, 11+ min ago   (661+ words) As betting expands into clinical trial outcomes, drugmakers may need to look beyond employees and scrutinize outside partners with access to sensitive information. Prediction markets have made it possible to trade on increasingly specific real-world outcomes. But they’ve also opened…...

1+ week, 1+ day ago   (772+ words) Gilead’s HIV PrEP medication Yeztugo is flying high, but the company will need to make inroads with the Black community to bolster growth and tackle historic health inequities. Gilead Sciences scored a landmark victory last year when the FDA approved…...

1+ week, 2+ day ago   (1122+ words) CAR-T’s commercial challenge isn’t making bigger batches. It’s making thousands of patient-specific manufacturing runs behave like one reliable system. In vivo aims to eliminate the batch altogether. At the Raritan, New Jersey, facility where Legend Biotech and Johnson & Johnson manufacture…...

1+ week, 3+ day ago   (840+ words) After two notable failures, the social anxiety R&D space gained a major player when Eli Lilly agreed to acquire AtaiBeckley this year. Drug developers have successfully tackled general anxiety with a number of innovations. But social anxiety disorder, which…...

2+ week, 22+ hour ago   (800+ words) Dealmaking in the autoimmune space is thriving as biotechs chase new targets with the potential to treat more conditions. No other drug category has reached the heady heights of GLP-1s in recent years, but immunology remains a strong contender as…...

2+ week, 1+ day ago   (373+ words) A Tufts analysis found that an AI clinical monitoring agent could deliver up to $21 million in value for a late-stage program in oncology R&D. But will the findings apply in more therapeutic areas? The pharma industry is investing aggressively in…...

2+ week, 3+ day ago   (425+ words) Late-stage drugs in pancreatic cancer, multiple myeloma and Alzheimer’s could pair treatment advances with major commercial upside. With Ozempic, Wegovy and Zepbound among the top 10 best-selling drugs in 2025, it’s no surprise that obesity treatments remain some of pharma’s most exciting…...

2+ week, 6+ day ago   (782+ words) What started as two neighbors trading shop talk has grown into Tyra Biosciences, a clinical-stage biotech company with a blockbuster potential pipeline. Tyra Biosciences is weeks away from the first clinical test of an unusual three-pronged strategy: use one oral…...